Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.

Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.

Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.

Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.

Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.

Abstract: Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Abstract: Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are disclosed.

Abstract: A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R.sup.3 and R.sup.4 which may be the same or different are each a hydrogen atom or a lower alkyl group, X is a group represented by the formula --S--, a group represented by the formula ##STR2## or a group represented by the formula ##STR3## and n is an integer of 1 to 6, provided that R.sup.3 and R.sup.4 are not simultaneously hydrogen atoms when n is 1.

Abstract: A benzothiazole derivative or a pharmacologically acceptable salt thereof of the following formula, as defined in the claims, which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective: ##STR1##

Abstract: A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective.

Abstract: A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective.A benzothiazole derivative represented by the following general formula (I): ##STR1## wherein R.sup.1 and R.sup.3 are either the same or different and represents a hydrogen atom, a lower alkyl group or a lower alkoxy group; R.sup.4 represents a group represented by the formula --(CH.sub.x)--.sub.q wherein q is a integer of from 1 to 4;R.sup.2 represents a hydrogen atom and;R.sup.5 and R.sup.6 are the same or different and each represent a hydrogen atom or a lower alkyl group; or a pharmacologically acceptable salt thereof.

Abstract: A pyridinium salt is useful as an antiulcer and is defined by the following formula. It includes a sulphenamide compound and a pyridinium compound. J is benzoimidazole, K is --S-- or --SSR, Z is hydroxy or oxyalkyl.

Abstract: A pyridinium salt useful as an antiulcer agent, defined by formula (I) is disclosed. It includes a sulphenamide compound and a pyridinium compound. J is benzimidazole, K is --S-- or --SSR-- and Z is hydroxy or alkoxy.

Abstract: Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Abstract: A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or different, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

Abstract: A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or differnt, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

Abstract: 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ols of the general formula: ##STR1##